{"id":"ezetimibe-simvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver transaminases"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":{"setId":"2ce219a2-1eeb-4ece-bb87-3810e593ca51","title":"EZETIMIBE AND SIMVASTATIN TABLET [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Simvastatin is an HMG-CoA reductase inhibitor that blocks the rate-limiting enzyme in hepatic cholesterol synthesis. Together, they provide complementary mechanisms to reduce LDL cholesterol levels more effectively than either agent alone.","oneSentence":"Ezetimibe and simvastatin work together to lower cholesterol by blocking intestinal cholesterol absorption and inhibiting hepatic cholesterol synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:04.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and mixed dyslipidemia"},{"name":"Cardiovascular risk reduction in patients requiring additional LDL-C lowering"}]},"trialDetails":[{"nctId":"NCT06437574","phase":"PHASE2","title":"Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2024-07-16","conditions":"Prostate Cancer","enrollment":140},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT04638400","phase":"PHASE4","title":"Anti-inflammatory Effects of Simvastatin","status":"TERMINATED","sponsor":"paresh Dandona","startDate":"2017-05-01","conditions":"Inflammation, Atherosclerosis, Hypercholesterolemia","enrollment":10},{"nctId":"NCT01414192","phase":"","title":"A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11-15","conditions":"Dyslipidemia, Hypercholesterolemia","enrollment":3215},{"nctId":"NCT00092651","phase":"PHASE3","title":"A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09","conditions":"Hypercholesterolemia","enrollment":1398},{"nctId":"NCT00541697","phase":"PHASE3","title":"Eze/Simva Switch Study in Diabetics (0653A-807)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-19","conditions":"Diabetes Mellitus, Type 2","enrollment":648},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT00551876","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":214},{"nctId":"NCT00651560","phase":"PHASE3","title":"Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11-01","conditions":"Hyperlipidemia","enrollment":167},{"nctId":"NCT00551447","phase":"PHASE3","title":"A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-01","conditions":"Coronary Disease","enrollment":616},{"nctId":"NCT00093899","phase":"PHASE3","title":"A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11","conditions":"Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia","enrollment":611},{"nctId":"NCT00650819","phase":"PHASE3","title":"Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06-01","conditions":"Hypercholesterolemia","enrollment":240},{"nctId":"NCT00552097","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-01","conditions":"Atherosclerosis, Hypercholesterolemia, Hyperlipoproteinemia Type II","enrollment":720},{"nctId":"NCT00092664","phase":"PHASE3","title":"An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01","conditions":"Hypercholesterolemia","enrollment":1104},{"nctId":"NCT00090298","phase":"PHASE3","title":"Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-04","conditions":"Hypercholesterolemia","enrollment":2815},{"nctId":"NCT00650663","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":247},{"nctId":"NCT00092716","phase":"PHASE3","title":"Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05","conditions":"Hypercholesterolemia","enrollment":655},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00157911","phase":"PHASE3","title":"A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Hypercholerolemia","enrollment":136},{"nctId":"NCT00653835","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolaemia, Atherosclerosis","enrollment":153},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00652301","phase":"PHASE3","title":"A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-07","conditions":"Cholesterol","enrollment":40},{"nctId":"NCT00651274","phase":"PHASE4","title":"Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-01","conditions":"Atherosclerosis, Hypercholesterolemia, Coronary Heart Disease","enrollment":144},{"nctId":"NCT00092612","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":372},{"nctId":"NCT00092599","phase":"PHASE3","title":"Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":410},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00090168","phase":"PHASE3","title":"Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01-27","conditions":"Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease","enrollment":435},{"nctId":"NCT00651391","phase":"PHASE3","title":"Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2003-10-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":28},{"nctId":"NCT00395603","phase":"PHASE3","title":"Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Cardiovascular Diseases, Diabetes Mellitus","enrollment":550},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT00157924","phase":"PHASE4","title":"Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":190},{"nctId":"NCT00442897","phase":"PHASE4","title":"Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Hypercholesterolemia","enrollment":229},{"nctId":"NCT00654628","phase":"PHASE4","title":"Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-08-01","conditions":"Hypercholesterolemia","enrollment":173},{"nctId":"NCT00166504","phase":"PHASE4","title":"Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10","conditions":"Hypercholesterolemia","enrollment":203},{"nctId":"NCT00423579","phase":"PHASE4","title":"The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-01","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":120},{"nctId":"NCT00653523","phase":"PHASE3","title":"Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":151},{"nctId":"NCT00496730","phase":"PHASE3","title":"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":256},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT00782184","phase":"PHASE3","title":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT00462748","phase":"PHASE3","title":"A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Hypercholesterolemia","enrollment":786},{"nctId":"NCT00092677","phase":"PHASE3","title":"An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01","conditions":"Aortic Stenosis","enrollment":1873},{"nctId":"NCT00479713","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-01","conditions":"Hypercholesterolemia","enrollment":618},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT03882905","phase":"PHASE3","title":"A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01-31","conditions":"Primary Hypercholesterolemia","enrollment":769},{"nctId":"NCT00092690","phase":"PHASE3","title":"MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-06","conditions":"Hypercholesterolemia","enrollment":1902},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT01420328","phase":"NA","title":"To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2011-05-01","conditions":"Inflammation","enrollment":20},{"nctId":"NCT00988364","phase":"PHASE4","title":"Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2007-03","conditions":"Metabolic Syndrome","enrollment":30},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT02534376","phase":"EARLY_PHASE1","title":"Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2015-09","conditions":"Prostate Cancer","enrollment":63},{"nctId":"NCT05613400","phase":"PHASE4","title":"Statin and Bone Health","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-04-13","conditions":"Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT01587235","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-03","conditions":"Dyslipidemia","enrollment":""},{"nctId":"NCT00652444","phase":"PHASE4","title":"Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09","conditions":"Hypercholesterolemia","enrollment":120},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00651014","phase":"PHASE4","title":"Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":82},{"nctId":"NCT00652431","phase":"PHASE1","title":"Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":18},{"nctId":"NCT00413972","phase":"PHASE3","title":"Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04","conditions":"Hypercholesterolemia","enrollment":392},{"nctId":"NCT01070966","phase":"","title":"Vytorin Reexamination Study (0653A-174)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)","enrollment":2089},{"nctId":"NCT00423488","phase":"PHASE3","title":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-12","conditions":"Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease","enrollment":93},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT01077830","phase":"","title":"An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-03","conditions":"Cancer","enrollment":1392},{"nctId":"NCT00724477","phase":"","title":"Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-10","conditions":"Primary Hypercholesterolemia","enrollment":1663},{"nctId":"NCT00652327","phase":"PHASE4","title":"Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":83},{"nctId":"NCT00909389","phase":"","title":"Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-11","conditions":"Hypercholesterolemia","enrollment":4748},{"nctId":"NCT00129402","phase":"PHASE3","title":"Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Hypercholesterolemia","enrollment":248},{"nctId":"NCT05080140","phase":"","title":"Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study","status":"UNKNOWN","sponsor":"Misr University for Science and Technology","startDate":"2019-06-01","conditions":"Hyperlipidemia; Mixed","enrollment":3},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04829149","phase":"","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-06-14","conditions":"Dyslipidemias","enrollment":5717},{"nctId":"NCT01035320","phase":"PHASE4","title":"Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01","conditions":"Diabetes Mellitus, Impaired Renal Function","enrollment":39},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT00477204","phase":"PHASE2","title":"Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Type 1 Diabetes Mellitus, Dyslipidemia","enrollment":9},{"nctId":"NCT00879710","phase":"NA","title":"Effect of Diabetes Mellitus on Cholesterol Metabolism","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":57},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT01420549","phase":"PHASE3","title":"Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-03","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":129},{"nctId":"NCT00819403","phase":"PHASE4","title":"Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-01","conditions":"Metabolic Syndrome","enrollment":15},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT03543774","phase":"PHASE4","title":"Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population","status":"UNKNOWN","sponsor":"Hue University of Medicine and Pharmacy","startDate":"2018-06-15","conditions":"Hypercholesterolemia, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT03771053","phase":"NA","title":"The Effect of Simvastatin Combined With Ezetimibe in Patients With Stable Angina and Diabetes","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2018-01-01","conditions":"Coronary Heart Disease","enrollment":240},{"nctId":"NCT02304926","phase":"NA","title":"Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia","status":"COMPLETED","sponsor":"Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","startDate":"2009-01","conditions":"Dyslipidemia","enrollment":42},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125},{"nctId":"NCT02378064","phase":"PHASE4","title":"Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation","status":"COMPLETED","sponsor":"CHEOL WHAN LEE, M.D., Ph.D","startDate":"2015-05","conditions":"Inflammation Plaque, Atherosclerotic, Coronary Disease, Renin-Angiotensin System","enrollment":50},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT00587678","phase":"NA","title":"Comprehensive Magnetic Resonance of Peripheral Arterial Disease","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2006-01","conditions":"Peripheral Artery Disease","enrollment":85},{"nctId":"NCT00385658","phase":"PHASE4","title":"Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Dyslipidemia","enrollment":75},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT02547402","phase":"PHASE1","title":"A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males","status":"COMPLETED","sponsor":"Complexa, Inc.","startDate":"2015-12","conditions":"Acute Kidney Injury","enrollment":10},{"nctId":"NCT00120289","phase":"PHASE3","title":"Niacin Plus Statin to Prevent Vascular Events","status":"TERMINATED","sponsor":"Axio Research. LLC","startDate":"2005-09","conditions":"Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident","enrollment":3414},{"nctId":"NCT02548936","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2015-04","conditions":"Atherosclerosis","enrollment":30},{"nctId":"NCT00738296","phase":"PHASE4","title":"Vytorin on Carotid Intima-media Thickness and Overall Rigidity","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2005-04","conditions":"Cardiovascular Diseases","enrollment":90}],"_emaApprovals":[],"_faersSignals":[{"count":126,"reaction":"DIARRHOEA"},{"count":125,"reaction":"ACUTE KIDNEY INJURY"},{"count":102,"reaction":"FATIGUE"},{"count":87,"reaction":"DYSPNOEA"},{"count":80,"reaction":"RHABDOMYOLYSIS"},{"count":79,"reaction":"MYALGIA"},{"count":78,"reaction":"DRUG INTERACTION"},{"count":69,"reaction":"DIZZINESS"},{"count":67,"reaction":"NAUSEA"},{"count":59,"reaction":"ASTHENIA"}],"_approvalHistory":[],"publicationCount":243,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 58235","Vytorin®","MK653A","MK0653A","Zetia"],"phase":"marketed","status":"active","brandName":"Ezetimibe + Simvastatin","genericName":"Ezetimibe + Simvastatin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezetimibe and simvastatin work together to lower cholesterol by blocking intestinal cholesterol absorption and inhibiting hepatic cholesterol synthesis. Used for Hypercholesterolemia and mixed dyslipidemia, Cardiovascular risk reduction in patients requiring additional LDL-C lowering.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}